FDA ACCEPTS MESOBLAST’S RESUBMISSION OF THE BIOLOGIC LICENSE
APPLICATION FOR REMESTEMCEL-L IN CHILDREN WITH STEROID-REFRACTORY
ACUTE GRAFT VERSUS HOST DISEASE AS A COMPLETE RESPONSE AND SETS
GOAL DATE OF AUGUST 2, 2023
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-16
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.035(3.18%) |
Mkt cap ! $1.255B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.14 | $1.07 | $7.906M | 7.156M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 68307 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 45868 | 7 |
View Market Depth
| Last trade - 10.23am 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.035 ( 7.91 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.20 | $1.07 | 1172832 | ||
| Last updated 10.44am 02/05/2024 ? | |||||
| MSB (ASX) Chart |